Laudanum are generally confined to controlling diarrhea, alleviating pain, and easing withdrawal symptoms in infants born to mothers addicted to heroin or other opioids. Recent enforcement action by the U.S. Food and Drug Administration (FDA) against manufacturers of paregoric and opium tincture suggests that opium tincture's availability in the U.S. may be in jeopardy. The terms "laudanum" and "tincture of opium" are generally interchangeable, but in contemporary medical practice the latter is used almost exclusively. Paracelsus, a 16th-century Swiss-German alchemist, experimented with various opium concoctions, and recommended opium for reducing pain. One of his preparations, a pill which he extolled as
Drug Houses of Australia Drug Houses of Australia Drug Houses of Australia (DHA) was originally established in 1936 as an amalgamation of seven Australian pharmaceutical companies, notably A. M. Bickford & Sons. In 1970, DHA was taken over by the British bank Slater Walker. Drug Houses of Australia is now a leading generic pharmaceutics and Chinese proprietary medicine (CPM) manufacturer based in Jurong, Singapore. It was sold to Strides Arcolab through a share purchase agreement with Haw Par Healthcare Limited, Singapore in September 2006 for approximately SGD$19.7 million. It is currently a part of Strides Arcolab which is listed on both the Indian stock